Sean Mcgarry

Array ( [id] => 17735018 [patent_doc_number] => 20220220477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => METHODS OF TREATING DISEASES ASSOCIATED WITH CELLS EXHIBITING ER STRESS OR WITH NEURAL TISSUE DAMAGE [patent_app_type] => utility [patent_app_number] => 17/610172 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17735026 [patent_doc_number] => 20220220485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => PD-L1 antisense oligonucleotides for use in tumor treatment [patent_app_type] => utility [patent_app_number] => 17/607616 [patent_app_country] => US [patent_app_date] => 2020-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18216670 [patent_doc_number] => 11591593 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Screening artificial nucleic acids by particle display [patent_app_type] => utility [patent_app_number] => 16/864703 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14659 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238600 [patent_doc_number] => 20200255834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => OLIGONUCLEOTIDE SEQUENCES TARGETING TRANSCRIPTION FACTOR TSC22D4 FOR THE TREATMENT OF INSULIN RESISTANCE [patent_app_type] => utility [patent_app_number] => 16/862930 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761742 [patent_doc_number] => 20220235354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => NUCLEIC ACID COMPOSITIONS AND METHODS OF MULTI-EXON SKIPPING [patent_app_type] => utility [patent_app_number] => 17/605955 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -101 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960321 [patent_doc_number] => 20220340901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => METHODS FOR THE TREATMENT OF RETINAL DYSTROPHIES BY EXON-SKIPPING STRATEGY [patent_app_type] => utility [patent_app_number] => 17/606574 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20818706 [patent_doc_number] => 12674168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-07 [patent_title] => Oligonucleotide compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/605997 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 136895 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17688233 [patent_doc_number] => 20220195525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => MOLECULAR MARKER DETECTION AND REGULATING METHODS IN DE-SERVITIZATION STATE OF CELLS [patent_app_type] => utility [patent_app_number] => 17/604707 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962940 [patent_doc_number] => 11896679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter [patent_app_type] => utility [patent_app_number] => 16/851636 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 53 [patent_no_of_words] => 36905 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962940 [patent_doc_number] => 11896679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter [patent_app_type] => utility [patent_app_number] => 16/851636 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 53 [patent_no_of_words] => 36905 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962940 [patent_doc_number] => 11896679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter [patent_app_type] => utility [patent_app_number] => 16/851636 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 53 [patent_no_of_words] => 36905 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962940 [patent_doc_number] => 11896679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter [patent_app_type] => utility [patent_app_number] => 16/851636 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 53 [patent_no_of_words] => 36905 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19013216 [patent_doc_number] => 11920134 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Compositions and methods for inhibiting expression of RRM2 genes [patent_app_type] => utility [patent_app_number] => 16/846535 [patent_app_country] => US [patent_app_date] => 2020-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 22403 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625870 [patent_doc_number] => 20220160885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => NUCLEIC ACID NANOSTRUCTURES CROSSLINKED WITH OLIGOLYSINE [patent_app_type] => utility [patent_app_number] => 17/602740 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16298039 [patent_doc_number] => 20200283762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => REDUCING NONSENSE-MEDIATED MRNA DECAY [patent_app_type] => utility [patent_app_number] => 16/839034 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17673060 [patent_doc_number] => 20220186227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => Therapeutic Targets for Oncogenic KRAS-Dependent Cancers [patent_app_type] => utility [patent_app_number] => 17/439439 [patent_app_country] => US [patent_app_date] => 2020-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611910 [patent_doc_number] => 20220154189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRAS ASSOCIATED DISEASES OR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/442301 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640692 [patent_doc_number] => 20220168430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => THERAPEUTIC METHODS FOR TREATING HEPATITIS B [patent_app_type] => utility [patent_app_number] => 17/440480 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612128 [patent_doc_number] => 20210030781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS [patent_app_type] => utility [patent_app_number] => 16/819900 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975775 [patent_doc_number] => 11492625 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => C5a binding nucleic acids [patent_app_type] => utility [patent_app_number] => 16/819102 [patent_app_country] => US [patent_app_date] => 2020-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 33 [patent_no_of_words] => 38415 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819102 [rel_patent_id] =>[rel_patent_doc_number] =>)